Advertisement
UK markets closed

  • FTSE 100

    8,078.86
    +38.48 (+0.48%)
     

  • FTSE 250

    19,601.98
    -117.39 (-0.60%)
     

  • AIM

    753.12
    -1.57 (-0.21%)
     

  • GBP/EUR

    1.1653
    +0.0008 (+0.07%)
     

  • GBP/USD

    1.2493
    +0.0030 (+0.24%)
     

  • Bitcoin GBP

    51,343.36
    -559.84 (-1.08%)
     

  • CMC Crypto 200

    1,387.46
    +4.89 (+0.35%)
     

  • S&P 500

    5,015.93
    -55.70 (-1.10%)
     

  • DOW

    37,885.27
    -575.65 (-1.50%)
     

  • CRUDE OIL

    82.52
    -0.29 (-0.35%)
     

  • GOLD FUTURES

    2,341.20
    +2.80 (+0.12%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,917.28
    -171.42 (-0.95%)
     

  • CAC 40

    8,016.65
    -75.21 (-0.93%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

US health officials say Ebola treatment trial to start soon in Liberia

Reuters - UK Focus

Jan 22 (Reuters) - U.S. health officials said on Thursday that they are planning to conduct larger phase 2/3 clinical trials starting in the next two weeks in Liberia to determine if an Ebola treatment being developed by GlaxoSmithKline (Other OTC: GLAXF - news) and another by Newlink Genetics (Munich: 4NX.MU - news) with Merck (Swiss: MER.SW - news) & Co are safe and effective.

Earlier Thursday, the World Health Organization said the epidemic in West Africa appears to be ebbing.

There have been 21,724 cases of Ebola reported in nine countries in the past year since the epidemic began in Guinea, including 8,641 deaths, according to the latest WHO figures.

The officials, speaking on a conference call, also said that they expect to soon start phase 1 and phase 2 clinical trials of the ZMapp Ebola virus treatment that is being developed by privately held Mapp Biopharmaceutical Inc. They said they believe they have produced enough ZMapp to supply the trials. (Reporting by Bill Berkrot and Caroline Humer; editing by Andrew Hay)